Jesup & Lemont maintains a Buy rating and $22 price target on Cross Country Healthcare (Nasdaq: CCRN).

The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE